3 Healthcare Stocks Every Retiree Should Consider

Source Motley_fool

Key Points

  • Pfizer is an out-of-favor drug maker that remains an industry leader.

  • Medtronic is a diversified medical device maker with an incredible dividend history.

  • Omega Healthcare is a senior housing REIT well-positioned to benefit from an aging population.

  • 10 stocks we like better than Pfizer ›

One of the biggest reasons to include some exposure to healthcare in your portfolio is simple logic: Healthcare isn't optional. If someone is ill, they need to address the problem, because the consequences of not doing so are likely to be far less desirable. If you are retired, meanwhile, you'll likely want to lean toward dividend-paying healthcare stocks.

Three strong options right now are drug giant Pfizer (NYSE: PFE), medical device giant Medtronic (NYSE: MDT), and senior housing-focused real estate investment trust (REIT) Omega Healthcare (NYSE: OHI). Here's why these stocks, with yields of up to 6.5%, could help power your retirement portfolio.

Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »

A line of 100 dollar bills planted in the ground.

Image source: Getty Images.

Pfizer is working through a rough patch

Pfizer is an industry-leading pharmaceutical company. It has a long and successful history of developing and marketing drugs. But there's a normal industry dynamic that is working against the company right now. New branded drugs get a limited period of patent protection. When a patent runs out, generic versions of the drug can be sold, which usually leads to a significant drop in revenues from the branded drug. Pfizer has several patent expirations on the horizon.

Drug companies are always looking for new drugs to offset the hit when branded drugs lose patent protection. Pfizer is working on a host of new drugs right now, but it appears that new drug launches (targeting weight loss, migraines, and oncology) won't line up with the company's patent expirations. That is actually fairly normal, since you can't really predict how research and development successes will play out.

Right now, Pfizer is deeply unloved and offers a lofty 6.5% dividend yield. Management is clear that the goal is to not only support the current dividend payment, but to grow it over the long term. The payout ratio is currently over 100%, so Pfizer is probably most appropriate for more aggressive investors. However, given the company's long and successful history, it is likely to muddle through this period just fine.

Medtronic is refocusing its business

The big draw with Medtronic is its 48-year-long streak of annual dividend increases. That puts this large and diversified medical device company just two years away from achieving Dividend King status. Now add to that a historically high 3.6% dividend yield, and you can see why more conservative dividend investors might appreciate owning Medtronic.

Medtronic's yield is so high because the company is in the middle of a business revamp. Essentially, it got bloated and inefficient, which is normal for large companies with long operating histories. To get back on track, Medtronic has been cutting costs and refocusing on its most profitable divisions. It has also been working on new products, such as its recently launched Hugo surgical robot.

If history is any guide, Medtronic will work through this difficult period and get back on the growth track. If you buy it now, you can collect an attractive and growing dividend while you wait. And when the company does work through this transition period, it is highly likely that Wall Street will again afford it a higher valuation.

Omega is through the hard part

Omega Healthcare is a REIT focused on senior housing properties, including nursing homes. During the coronavirus pandemic that was a very difficult business to be in. However, unlike many of the company's peers, Omega didn't cut its dividend. To be fair, the dividend hasn't been increased since 2019, but it is clear that the REIT places a high value on paying a reliable dividend. The yield is a very attractive 5.8%.

The big draw here, however, is that Omega has already worked through the rough patch it faced. It is now growing its business again. Longer term, the REIT's opportunity lies in serving an aging population. There's nothing fancy about it; as people age, they need more help. Omega owns the properties that provide that help. You can help yourself to the REIT's lofty yield as it moves further from the difficult COVID period.

Retirees tend to like dividends

If you are retired, you are likely looking for your investment portfolio to help supplement your Social Security checks. Three great healthcare sector options every retiree should consider right now are high-yielders Pfizer, Medtronic, and Omega Healthcare. They are very different businesses and, when all is said and done, you may even decide you want to own all of them.

Should you buy stock in Pfizer right now?

Before you buy stock in Pfizer, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pfizer wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $475,926!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,296,608!*

Now, it’s worth noting Stock Advisor’s total average return is 981% — a market-crushing outperformance compared to 205% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of May 8, 2026.

Reuben Gregg Brewer has positions in Medtronic. The Motley Fool has positions in and recommends Medtronic and Pfizer. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
MicroStrategy Shares are Performing Better than Bitcoin In 2026, But How?MicroStrategy stock is up nearly 3% at press time, trading above $137 as markets opened on March 9. Strategy just announced another 17,994 BTC purchase for $1.28 billion.The stock trades 57% lower ove
Author  Beincrypto
Mar 10, Tue
MicroStrategy stock is up nearly 3% at press time, trading above $137 as markets opened on March 9. Strategy just announced another 17,994 BTC purchase for $1.28 billion.The stock trades 57% lower ove
placeholder
What to Expect From NVIDIA Stock Price in April 2026?NVIDIA (NASDAQ: NVDA) stock price trades at $177.64 on the 2-day chart, up 5.31% over the past days but still down 6% year-to-date. April sits at a unique inflection for the stock. The Iran conflict c
Author  Beincrypto
Apr 08, Wed
NVIDIA (NASDAQ: NVDA) stock price trades at $177.64 on the 2-day chart, up 5.31% over the past days but still down 6% year-to-date. April sits at a unique inflection for the stock. The Iran conflict c
placeholder
MicroStrategy Posts $12.5 Billion Q1 2026 Loss on Bitcoin SlideMicroStrategy Inc posted a $12.54 billion net loss for the first quarter of 2026, the largest in the firm’s history. The deficit reflects a $14.46 billion unrealized markdown on its Bitcoin (BTC) hold
Author  Beincrypto
May 06, Wed
MicroStrategy Inc posted a $12.54 billion net loss for the first quarter of 2026, the largest in the firm’s history. The deficit reflects a $14.46 billion unrealized markdown on its Bitcoin (BTC) hold
placeholder
3 Oil Stocks To Watch In May 2026Oil stocks trade at a $40 premium to where JP Morgan thinks 2026 fundamentals settle. The gap is pure geopolitical risk from the US-Iran conflict.Three names just reported Q1 2026 results this week, e
Author  Beincrypto
May 07, Thu
Oil stocks trade at a $40 premium to where JP Morgan thinks 2026 fundamentals settle. The gap is pure geopolitical risk from the US-Iran conflict.Three names just reported Q1 2026 results this week, e
placeholder
XRP Market Now Controlled By Whales? Dominance Reaches 91% On BinanceUS spot XRP exchange-traded funds recorded net inflows of $11.28 million on Tuesday, marking their second consecutive positive day — a streak that coincides with a sharp shift in who is actually
Author  NewsBTC
22 hours ago
US spot XRP exchange-traded funds recorded net inflows of $11.28 million on Tuesday, marking their second consecutive positive day — a streak that coincides with a sharp shift in who is actually
goTop
quote